Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates  

作　　者：Xiaoyu Zhu Shihan Huo Chao Xue Bo An Jun Qu 

机构地区：[1]Department of Pharmaceutical Sciences,School of Pharmacy&Pharmaceutical Sciences,University at Buffalo,State University of New York,Buffalo,NY,14214,USA [2]New York State Center of Excellence in Bioinformatics&Life Sciences,Buffalo,NY,14203,USA [3]Department of Chemical and Biological Engineering,School of Engineering and Applied Science,University at Buffalo,State University of New York,Buffalo,NY,14260,USA [4]Exploratory Biomarker,In-vitro/In-vivo Translation,R&D Research,GlaxoSmithKline Pharmaceuticals,1250 South Collegeville Rd,Collegeville,PA,19426,USA

出　　处：《Journal of Pharmaceutical Analysis》2020年第3期209-220,共12页药物分析学报（英文版）

摘　　要：The past few years have witnessed enormous progresses in the development of antibody-drug conjugates(ADCs).Consequently,comprehensive analysis of ADCs in biological systems is critical in supporting discovery,development and evaluation of these agents.Liquid chromatography-mass spectrometry(LC-MS)has eme rged as a promising and versatile tool for ADC analysis across a wide range of scenarios,owing to its multiplexing ability,rapid method development,as well as the capability of analyzing a variety of targets ranging from small-molecule payloads to the intact protein with a high,molecular resolution.However,despite this tremendous potential,challenges persist due to the high complexity in both the ADC molecules and the related biological systems.This review summarizes the up-to-date LC-MS-based strategies in ADC analysis and discusses the challenges and opportunities in this rapidly-evolving field.

关 键 词：Antibody-drug conjugate(ADC) Liquid chromatography-mass spectrometry(LCMS) Drug-to-antibody ratio(DAR) 

分 类 号：R392-33[医药卫生—免疫学]